Le Lézard
Classified in: Health
Subjects: NPT, SVY

JOMS study: Oral biopsies provide opportunity to discuss oral cancer risk factors



ROSEMONT, Ill., Oct. 6, 2017 /PRNewswire-USNewswire/ -- A new study suggests a doctor-patient discussion of risk factors at the time of oral cancer biopsies could be "an important initial step" toward behavior changes of at-risk patients.

The experts in face, mouth and jaw surgery(TM) - The American Association of Oral and Maxillofacial Surgeons (AAOMS), the professional organization representing more than 9,500 oral and maxillofacial surgeons in the United States, supports its fellows' and members' ability to practice their specialty through education, research and advocacy. AAOMS fellows and members comply with rigorous continuing education requirements and submit to periodic office anesthesia evaluations. Visit MyOMS.org for additional information about oral and facial surgery.

The study, published in the October issue of the Journal of Oral and Maxillofacial Surgery, encourages doctors to advise their oral cancer biopsy patients of the risk factors associated with continued tobacco and alcohol use.

"Knowledge of the relation between oral biopsy and behavior change can be very important for oral and maxillofacial surgeons and other clinicians who deliver diagnoses and arrange for disease treatment because these providers are in a unique position to influence at-risk patients and lower the overall use of the chief etiologic agents responsible for oral cancer," the authors said.

The study, published in the official journal of the American Association of Oral and Maxillofacial Surgeons, looked at the behavior changes of 605 patients to determine the association between changes in alcohol or tobacco use and an oral biopsy (an examination of cells or tissues removed from a body to check for the presence of a disease). Adults diagnosed with hyperkeratosis (a thickening of the skin's outer layer), dysplasia (abnormal precancerous tissue), or carcinoma (a type of cancer) were included in the study. 

Larger percentages of patients with more severe clinical diagnoses quit smoking and stopped drinking alcohol following their biopsies, the study found. A higher percentage of patients with dysplasia quit than those with hyperkeratosis, a promising finding because dysplasia has shown to be potentially reversible, researchers wrote.

Nearly 36 percent of tobacco users at the time of their biopsy quit smoking after the exam, and almost 9 percent who were using alcohol stopped drinking after undergoing a biopsy.

Age and race were connected to behavior changes, emphasizing "the need for clinicians to address cessation with all types of patients," the researchers concluded. The youngest respondents ? ages 21 to 52 ? were 3.7 times more likely to continue to smoke before or after a biopsy. White non-Hispanics were less likely to quit drinking alcohol before and after biopsy than other races.

During diagnosis, doctors can provide "objective, personal and tangible evidence of physical harm resulting from" tobacco and alcohol use to potentially change patient behavior, researchers wrote.

"Informing a patient that surgical removal of a suspicious lesion is recommended enlightens the patient to the fact that the patient's health could be in jeopardy and that a painful procedure is recommended to determine this possibility," authors wrote. "Also, delivery of the biopsy diagnosis serves as an opportunity to highlight unequivocally how the patient's tissues are being affected and how cessation would be directly beneficial."

The authors of "Is Oral Biopsy Associated With Change in Tobacco or Alcohol Use?" ? all from the University of North Carolina in Chapel Hill, N.C. ? are: Tiffany M. Peters, DDS, MS, Adjunct Assistant Professor, Department of Diagnostic Sciences; Ceib Phillips, PhD, MPH, Assistant Dean for Graduate/Advanced Education, Department of Orthodontics; and Valerie A. Murrah, DMD, MS, Professor and Chair, Department of Diagnostic Sciences; Director, Division of Oral and Maxillofacial Pathology.

The full article can be accessed at www.joms.org/article/S0278-2391(17)30337-3/fulltext.

The Journal of Oral and Maxillofacial Surgery is published by the American Association of Oral and Maxillofacial Surgeons to present to the dental and medical communities comprehensive coverage of new techniques, important developments and innovative ideas in oral and maxillofacial surgery. Practice-applicable articles help develop the methods used to handle dentoalveolar surgery, facial injuries and deformities, TMJ disorders, oral and head and neck cancer, jaw reconstruction, anesthesia and analgesia. The journal also includes specifics on new instruments and diagnostic equipment, and modern therapeutic drugs and devices.

CONTACT: Jolene Kremer, Associate Executive Director, Communications & Publications,
American Association of Oral and Maxillofacial Surgeons
Phone: 847-233-4336
Fax: 847-678-6286
jkremer@aaoms.org
www.AAOMS.org

SOURCE American Association of Oral & Maxillofacial Surgeons


These press releases may also interest you

at 12:16
HealthCombix today announced that it has partnered with San Francisco based NuCypher to explore distributed security technology integrations to solve privacy, consent, and identity challenges in healthcare around the globe. HealthCombix, a...

17 fév 2018
The next frontier is truly the mind. To explore our vast galaxy, one of the most useful avenues has been Virtual Reality (VR). What makes VR so special is its ability to allow you to transport into another world without literally having to move an...

17 fév 2018
AbbVie , a global research and development-based biopharmaceutical company, today presented new positive results from the pivotal Phase 3 ultIMMa-1 and ultIMMa-2 replicate clinical trials that evaluated the safety and efficacy of risankizumab (150...

17 fév 2018
AbbVie , a global research and development-based biopharmaceutical company, today presented new positive results from a Phase 2b dose-ranging study evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult...

17 fév 2018
Evolus, Inc. today announced the presentation of data from the Phase III comparative clinical trial of its investigational prabotulinumtoxinA 900 kilodalton (kDa) neuromodulator at the American Academy of Dermatology (AAD) meeting....

17 fév 2018
Veterans gathered to bond and learn adaptive winter sports techniques from experienced instructors at the Arizona Snowbowl. During the two-day-adaptive ski and snowboard experience with Wounded Warrior Project® (WWP), some veterans with injuries...




News published on 6 october 2017 at 02:30 and distributed by: